Join the Leading Industry Forum Specifically Dedicated to Progressing More RNAi Therapeutics Towards Approval

RNAi-based therapeutics have been proven to be a successful treatment for liver diseases with a number of approvals by both the FDA and the EMA. For the very first time, we have seen the release of FDA guidance on clinical pharmacology considerations offering some guidance for drug developers to advance their pipelines.

Despite this, targeted delivery, process development, selectivity and limited half-life remain big challenges to overcome. The field is poised for the RNAi revolution. Join this conference to:

	Deep dive into delivery mechanisms, including lipid conjugates, that are targeting the skin, eyes, and CNS that is expanding the therapeutic target space for siRNA therapies with, Eli Lilly & Altamira Therapeutics
	Hear key clinical updates of siRNA candidates tackling oncology indications as well as new targets that are being explored with Siranomics
	Uncover computational modeling approaches to enhance target identification, improve biological understanding, and fast-track siRNA discovery with e-Therapeutics & Tallas Biotech
	Revealing next-generation dual targeting siRNAs with improved tolerability and efficacy for robust silencing in the brain with University of Massachusetts & Argonaute RNA
	Learn about the strategies for successful scale-up and ways to tackle quick turnaround times to meet the demands for in-person trials whilst ensuring robust production processes with Olix Pharmaceuticals